PUBLISHER: DelveInsight | PRODUCT CODE: 2167083
PUBLISHER: DelveInsight | PRODUCT CODE: 2167083
DelveInsight's, "Respiratory Syncytial Virus - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Respiratory Syncytial Virus: Understanding
Respiratory Syncytial Virus: Overview
RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults. RSV spreads through respiratory droplets and can survive on surfaces for several hours. While most infections are self-limiting, severe cases may require hospitalization, and preventive measures such as good hygiene and vaccination are essential in managing its spread.
Symptoms of RSV infection usually include runny nose; decrease in appetite; coughing; sneezing fever; wheezing. These symptoms usually appear in stages and not all at once. In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties. RSV can also cause more severe infections such as bronchiolitis, an inflammation of the small airways in the lung, and pneumonia, an infection of the lungs. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age. People infected with RSV usually show symptoms within 4 to 6 days after getting infected.
RSV is highly contagious and it spreads through droplet transmission. When a person with the infection coughs or sneezes, secretions from their respiratory tract containing the virus are passed out into the air. A person is usually contagious for 3 to 8 days, but young children and those with a weakened immune system may still be able to pass it on for up to 4 weeks, even after their symptoms disappear. People infected with RSV are usually contagious for 3 to 8 days. However, some infants, and people with weakened immune systems, can continue to spread the virus even after they stop showing symptoms, for as long as 4 weeks.
Diagnosis of Respiratory Syncytial Virus (RSV) infections primarily involves clinical evaluation based on symptoms such as wheezing, coughing, and difficulty breathing, particularly in infants and young children. Laboratory tests include antigen detection, polymerase chain reaction (PCR) assays, and viral culture from nasal or throat swabs. Rapid diagnostic tests can provide results within hours, aiding in the timely management of the infection. Chest X-rays and blood tests may be performed to assess the severity of the disease and rule out other conditions.
Most RSV infections resolve on their own in a week or two. Antiviral drug called palivizumab is available to prevent severe RSV illness in high-risk infants (born prematurely or with congenital heart disease or chronic lung disease). However, the use of palivizumab is limited as it can only be used in certain children considered at high risk for complications, does not help cure or treat children already suffering from serious RSV disease, and cannot prevent RSV infection.
"Respiratory Syncytial Virus- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory Syncytial Virus pipeline landscape is provided which includes the disease overview and Respiratory Syncytial Virus treatment guidelines. The assessment part of the report embraces, in depth Respiratory Syncytial Virus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Respiratory Syncytial Virus Emerging Drugs Chapters
This segment of the Respiratory Syncytial Virus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Respiratory Syncytial Virus Emerging Drugs
Zelicapavir (EDP-938) is an oral, once-daily antiviral developed by Enanta Pharmaceuticals for the treatment of respiratory syncytial virus (RSV) infection. It is a potent inhibitor of the RSV nucleoprotein (N-protein), targeting the virus's replication machinery. By inhibiting the N-protein, zelicapavir prevents viral replication and the production of new virions, thereby differing from RSV fusion inhibitors, which act by blocking viral entry. Zelicapavir, Enanta's lead N-protein inhibitor, is being developed for the treatment of RSV infection, and has been granted Fast Track designation by the US Food and Drug Administration. Zelicapavir is a nanomolar inhibitor of both RSV-A and RSV-B activity. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.
SCB-1022, developed by Clover Biopharmaceuticals, is a recombinant bivalent respiratory combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. The vaccine is based on prefusion-stabilized F (PreF) protein subunit antigens produced using Clover's Trimer-Tag vaccine technology platform, with the aim of inducing neutralizing antibody responses against both respiratory viruses. SCB-1022 is being evaluated primarily in older adults aged 60-85 years, a population at increased risk of severe respiratory disease. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.
mRNA-1365 is an investigational combination respiratory vaccine developed by Moderna, Inc. that targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The vaccine is designed as a part of its respiratory vaccine portfolio to address major causes of lower respiratory tract infections, particularly in pediatric populations and other vulnerable groups. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.
MDL-001 is an investigational, oral, direct-acting broad-spectrum antiviral developed by Model Medicines for multiple respiratory and hepatic viral infections, including respiratory syncytial virus (RSV). The company describes MDL-001 as a non-nucleoside inhibitor that targets the conserved RdRp Thumb-1 allosteric pocket of viral RNA-dependent RNA polymerases, thereby blocking viral RNA synthesis. For RSV, Model Medicines reported in vitro antiviral activity with an EC50 of 79.4 nM, representing approximately a 416-fold improvement in potency compared with ribavirin in the company's testing. Currently, the drug is in the Preclinical stage of its development for the treatment of Respiratory Syncytial Virus (RSV) infections.
Respiratory Syncytial Virus: Therapeutic Assessment
This segment of the report provides insights about the different Respiratory Syncytial Virus drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 50+ key companies which are developing the therapies Respiratory Syncytial Virus. The companies which have their Respiratory Syncytial Virus drug candidates in the most advanced stage, i.e. Phase II include, Enanta Pharmaceuticals and others.
DelveInsight's report covers around 55+ products under different phases of clinical development like
Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Respiratory Syncytial Virus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory Syncytial Virus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory Syncytial Virus drugs.
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Respiratory Syncytial Virus: Overview
Pipeline Therapeutics
Therapeutic Assessment
Respiratory Syncytial Virus- DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company Name
Mid Stage Products (Phase II)
Zelicapavir: Enanta Pharmaceuticals
Early Stage Products (Phase I)
mRNA-1365: Moderna, Inc.
Preclinical and Discovery Stage Products
MDL-001: Model Medicines
Inactive Products
Respiratory Syncytial Virus Key Companies
Respiratory Syncytial Virus Key Products
Respiratory Syncytial Virus - Unmet Needs
Respiratory Syncytial Virus - Market Drivers and Barriers
Respiratory Syncytial Virus - Future Perspectives and Conclusion
Respiratory Syncytial Virus Analyst Views
Respiratory Syncytial Virus Key Companies